Real-world data-based assessment of therapy-related myeloid neoplasms after poly(ADP-ribose) polymerase inhibitor treatment in ovarian cancer

Key Points

• Therapy-related myeloid neoplasms are increasingly common among ovarian cancer survivors.
• Continued monitoring is necessary, especially for patients treated with PARP inhibitors.
• Real-world data illustrates the need for awareness of long-term hematologic effects after treatment.
• Understanding risk factors may enhance survivorship care strategies for ovarian cancer patients.